Literature DB >> 10446818

Analysis of two human leukocyte antigen-linked polymorphic heat shock protein 70 genes in patients with severe sepsis.

S Schroeder1, M Reck, A Hoeft, F Stüber.   

Abstract

OBJECTIVE: To determine whether the genotype and allelic frequencies of two human leukocyte antigen-linked bi-allelic 70-kilodalton heat shock protein (HSP70) gene polymorphisms are associated with susceptibility to and outcome of severe sepsis. Furthermore, we investigated a possible linkage between HSP70 gene polymorphisms and the previously reported and mortality-related tumor necrosis factor-beta (TNF-beta) NcoI gene polymorphism.
DESIGN: Consecutive entry study of patients with severe sepsis.
SETTING: Surgical intensive care unit in a university hospital. PATIENTS: Eighty-seven patients with a diagnosis of severe sepsis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We studied two bi-allelic polymorphisms within the coding region of the constitutively expressed HSP70-HOM C/T, and the stress-inducible HSP70-2 G/A in patients with severe sepsis. The HSP70-HOM Ncol, HSP70-2 Pstl, and TNF-beta NcoI polymorphisms were identified by means of the polymerase chain reaction followed by restriction analysis of the polymerase chain reaction product. No significant differences in genotype and allelic frequencies were observed for both HSP70 gene polymorphisms between the 87 patients and the 110 healthy Caucasians serving as the control group. In addition, no differences in genotype and allelic frequencies between surviving and nonsurviving patients were detected. The allelic frequencies in the group of nonsurvivors were 0.8 for the HSP70-HOM C allele and 0.2 for the HSP70-HOM T allele vs. 0.87 and 0.13 for the survivors (p > .05). The frequency for the HSP70-2 G allele was 0.36 and 0.64 for the HSP70-2 A allele in the group of nonsurvivors vs. 0.41 and 0.59 for the survivors (p > .05). Analysis of a possible linkage between HSP70 and TNF-beta genotypes resulted in a significant association (odds ratio, 4.15; p < .01) of the HSP70-2 A/A homozygous genotype and the TNFB2/B2 homozygous genotype, which is reported to be a genomic marker for a poor prognosis in severe sepsis.
CONCLUSIONS: Our data show that the bi-allelic NcoI and PstI polymorphisms within the HSP70-HOM and HSP70-2 locus, respectively, are associated with neither susceptibility to nor outcome of severe sepsis. Moreover, we found a linkage between HSP70-2 A homozygotes and the previously reported and mortality-related homozygous genotype, TNFB2/B2, in patients suffering from severe sepsis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446818     DOI: 10.1097/00003246-199907000-00006

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  14 in total

1.  Heat shock protein 70 gene polymorphisms are associated with paranoid schizophrenia in the Polish population.

Authors:  Malgorzata Kowalczyk; Aleksander Owczarek; Renata Suchanek; Monika Paul-Samojedny; Anna Fila-Danilow; Paulina Borkowska; Krzysztof Kucia; Jan Kowalski
Journal:  Cell Stress Chaperones       Date:  2013-07-28       Impact factor: 3.667

2.  Ethical considerations in the collection of genetic data from critically ill patients: what do published studies reveal about potential directions for empirical ethics research?

Authors:  B D Freeman; C R Kennedy; H L Frankel; B Clarridge; D Bolcic-Jankovic; E Iverson; E Shehane; A Celious; B A Zehnbauer; T G Buchman
Journal:  Pharmacogenomics J       Date:  2009-12-08       Impact factor: 3.550

3.  Relationship of HLA-B*51 and HLA-B*52 alleles and TNF-α-308A/G polymorphism with susceptibility to Takayasu arteritis: a meta-analysis.

Authors:  Si Chen; Haixia Luan; Liubing Li; Xiaoli Zeng; Tian Wang; Yongzhe Li; Hui Yuan
Journal:  Clin Rheumatol       Date:  2016-11-04       Impact factor: 2.980

4.  Effects of schisandrin B pretreatment on tumor necrosis factor-alpha induced apoptosis and Hsp70 expression in mouse liver.

Authors:  S P Ip; C T Che; Y C Kong; K M Ko
Journal:  Cell Stress Chaperones       Date:  2001-01       Impact factor: 3.667

5.  A protocol comparison for the analysis of heat shock protein A1B +A1538G SNP.

Authors:  Carmen L Contreras-Sesvold; Nyamkhishig Sambuughin; Andrei Blokhin; Patricia A Deuster
Journal:  Cell Stress Chaperones       Date:  2009-08-06       Impact factor: 3.667

6.  Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis.

Authors:  Jose Garnacho-Montero; Teresa Aldabo-Pallas; Carmen Garnacho-Montero; Aurelio Cayuela; Rocio Jiménez; Sonia Barroso; Carlos Ortiz-Leyba
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

Review 7.  Human Leukocyte Antigen DQB1 (HLA-DQB1) Polymorphisms and the Risk for Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Peng-Peng Jin; Li-Li Sun; Bo-Jun Ding; Na Qin; Bin Zhou; Feng Xia; Li Li; Li-Juan Liu; Xue-Dong Liu; Gang Zhao; Wen Wang; Yan-Chun Deng; Shuang-Xing Hou
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

Review 8.  Bench-to-bedside review: understanding genetic predisposition to sepsis.

Authors:  Jesús Villar; Nicole Maca-Meyer; Lina Pérez-Méndez; Carlos Flores
Journal:  Crit Care       Date:  2004-04-29       Impact factor: 9.097

9.  Association between heat shock protein 70 gene polymorphisms and clinical outcomes in intensive care unit patients with sepsis.

Authors:  Kartik Ramakrishna; Srinivasan Pugazhendhi; Jayakanthan Kabeerdoss; John Victor Peter
Journal:  Indian J Crit Care Med       Date:  2014-04

10.  Analysis of heat shock protein 70 gene polymorphisms Mexican patients with idiopathic pulmonary fibrosis.

Authors:  Arnoldo Aquino-Gálvez; Georgina González-Ávila; Martha Pérez-Rodríguez; Oswaldo Partida-Rodríguez; Miriam Nieves-Ramírez; Inocencio Piña-Ramírez; Gustavo Ramírez-Martínez; Manuel Castillejos-López; Marco Checa; Victor Ruiz; Francisco Urrea; Bettina Sommer; Joaquin Zúñiga; Moisés Selman
Journal:  BMC Pulm Med       Date:  2015-10-24       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.